Market news

Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. Read why EVO stock is a Buy.

Investment Update: Long article based on a reader request.

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.

Tipranks Press Release.

Detailed price information for Evotec Se (EVO-Q) from The Globe and Mail including charting and trades.

The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.

LOS ANGELES, August 03, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N

PALO ALTO, Calif., July 23, 2026--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets.

Opportunities span cytotoxicity, phenotypic and morphological assays, flow cytometry, and pharma and biotech demand. Asia-Pacific and Europe expansion, rare-disease models, single-cell services, and patient-derived and cardiac organoid platforms offer further potential. Cell-Based Assay Services for Preclinical Use Only Market Cell-Based Assay Services for Preclinical Use Only Market Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Cell-Based Assay Services for Preclinical Use Only Global Market O

Despite a challenging quarter with revenue declines, Evotec SE (EVO) focuses on liquidity growth, strategic partnerships, and cost-saving initiatives to drive future success.

Evotec (NASDAQ:EVO) reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements. Chief

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.